MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Pfizer

Fermé

SecteurSoins de santé

24.31 -1.58

Résumé

Variation du prix de l'action

24h

Actuel

Min

24.31

Max

24.86

Chiffres clés

By Trading Economics

Revenu

-4.1B

411M

Ventes

63M

18B

P/E

Moyenne du Secteur

17.972

63.778

BPA

0.63

Rendement du dividende

6.79

Marge bénéficiaire

2.314

Employés

81,000

EBITDA

-4.3B

2.5B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+23.81% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

6.79%

2.39%

Prochains Résultats

29 avr. 2025

Date du Prochain Dividende

13 juin 2025

Date du Prochain Détachement de Dividende

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7.5B

144B

Ouverture précédente

25.89

Clôture précédente

24.31

Sentiment de l'Actualité

By Acuity

45%

55%

165 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Pfizer Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 mars 2025, 07:34 UTC

Acquisitions, Fusions, Rachats

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18 mars 2025, 17:26 UTC

Acquisitions, Fusions, Rachats

Pfizer to Dispose of Remaining Shareholding in Haleon

4 févr. 2025, 18:52 UTC

Principaux Mouvements du Marché

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

4 févr. 2025, 14:58 UTC

Résultats
Principaux Mouvements du Marché

Pfizer Shares Rise on Better-Than-Expected 4Q

26 mars 2025, 22:29 UTC

Actualités

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mars 2025, 19:19 UTC

Actualités

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mars 2025, 17:39 UTC

Actualités

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

18 mars 2025, 16:58 UTC

Acquisitions, Fusions, Rachats

Haleon Intends to Cancel Purchased Ordinary Shares

18 mars 2025, 16:57 UTC

Acquisitions, Fusions, Rachats

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18 mars 2025, 16:56 UTC

Acquisitions, Fusions, Rachats

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18 mars 2025, 16:56 UTC

Acquisitions, Fusions, Rachats

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18 mars 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Haleon Takes Note of Announcement

18 mars 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18 mars 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

Citigroup: This Is Subject to Customary Closing Conditions

18 mars 2025, 16:50 UTC

Acquisitions, Fusions, Rachats

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18 mars 2025, 16:49 UTC

Acquisitions, Fusions, Rachats

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18 mars 2025, 16:49 UTC

Acquisitions, Fusions, Rachats

Citigroup: Bookbuilding Period Will Commence Immediately

18 mars 2025, 16:49 UTC

Acquisitions, Fusions, Rachats

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18 mars 2025, 16:48 UTC

Acquisitions, Fusions, Rachats

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

18 mars 2025, 16:47 UTC

Acquisitions, Fusions, Rachats

Citigroup:: Amount Is Pfizer's Entire Residual Shareholding in Haleon

18 mars 2025, 16:47 UTC

Acquisitions, Fusions, Rachats

Citigroup: This Represents Approx 7.3% Stake in Haleon

18 mars 2025, 16:46 UTC

Acquisitions, Fusions, Rachats

Citigroup: Pfizer Intends to Sell Approx 662M Ordinary Shares in Haleon

17 mars 2025, 09:00 UTC

Actualités

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

14 févr. 2025, 11:38 UTC

Actualités
Résultats

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 févr. 2025, 11:30 UTC

Actualités
Résultats

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 févr. 2025, 12:00 UTC

Actualités

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 févr. 2025, 19:34 UTC

Actualités

RFK Jr. Clears Committee Vote, Putting Him on Track to Become Health Secretary -- 3rd Update

4 févr. 2025, 19:10 UTC

Actualités

Pfizer Falls on RFK's Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered. -- Barrons.com

4 févr. 2025, 18:51 UTC

Actualités

RFK Jr. Clears Committee Vote, Putting Him on Track to Become Health Secretary -- 2nd Update

Comparaison

Variation de prix

Pfizer prévision

Objectif de Prix

By TipRanks

23.81% hausse

Prévisions sur 12 Mois

Moyen 30.58 USD  23.81%

Haut 36 USD

Bas 27 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

15 ratings

6

Achat

9

Maintien

0

Vente

Score Technique

By Trading Central

24.52 / 25.23Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

165 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.